Abstracts tagged "spondyloarthritis"

Abstract Number: 0817 • ACR Convergence 2021
Biosimilar Infliximab Therapy in Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis: A Long-term Follow-up Study on Infliximab-naive Patients and Switched Patients from the Originator to the Biosimilar CT-P13
Hubert MAROTTE¹, Maryse Assing², Nadir Mammar², Yves Brault³ and Bruno Fautrel⁴, ¹Rheumatology department - Unisersity Hospital of Saint-Etienne, Saint-Etienne, France, ²Inflammation & Immunology - Pfizer, Paris, France, ³Pfizer, Paris, France, ⁴Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France
Background/Purpose: ReFLECT study has been carried out to investigate real life use of CT-P13, the first monoclonal antibody biosimilar to infliximab (IFX) originator.Methods: ReFLECT is…
Abstract Number: 0923 • ACR Convergence 2021
Minimal Impact of the COVID-19 Pandemic on Patient-Reported Disease Activity and Health-Related Quality of Life in Patients with Ankylosing Spondylitis Receiving Bimekizumab: Post Hoc Analyses from a Phase 2b Study
Philip Robinson¹, Pedro Machado², Nigil Haroon³, Lianne Gensler⁴, John Reveille⁵, Vanessa Taieb⁶, Thomas Vaux⁶, Carmen Fleurinck⁷, Marga Oortgiesen⁸, Natasha de Peyrecave⁷ and Atul Deodhar⁹, ¹University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia, ²Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³Division of Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Raleigh, NC, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that inhibits both interleukin (IL)-17A and IL-17F, has been demonstrated to be efficacious and well tolerated in patients…
Abstract Number: 1307 • ACR Convergence 2021
Uveitis in Spondyloarthritis Patients. Is There Any Specific Clinical Picture?
MARIA LLOP VILALTELLA¹, Mireia moreno¹, Marta Arévalo¹, Jordi Gratacós¹, Maxime Dougados² and Clementina López Medina³, ¹Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí I3PT, Sabadell, Spain, ²Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ³Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France
Background/Purpose: Uveitis is the most frequent extra-musculoskeletal manifestation in Spondyloarhtritis (SpA). Moreover, up to 50% of patients with an acute episode of uveitis develop recurrent…
Abstract Number: 1722 • ACR Convergence 2021
Risk of Pre-eclampsia and Impact of Disease Activity and Anti-rheumatic Treatment in Women with Rheumatoid Arthritis, Axial Spondylarthritis, and Psoriatic Arthritis – A Collaborative Matched Cohort Study from Sweden and Denmark
Anne Emilie Secher¹, Karin Hellgren², Bente Glintborg³, Ane Rom⁴, Merete Hetland⁵ and Fredrik Granath², ¹COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Frederiksberg, Denmark, ²Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ³COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, Glostrup, Denmark, ⁴The Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark, ⁵DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark
Background/Purpose: Pre-eclampsia is a pregnancy-related syndrome with potentially fatal outcomes. In RA, high disease activity has been associated to adverse pregnancy outcomes such as preterm…
Abstract Number: 1922 • ACR Convergence 2021
Early and Accurate Diagnosis of Patient with Axial Spondyloarthritis Using Machine Learning: A Predictive Analysis from Electronic Health Records in United Kingdom
Raj Sengupta¹, Shruti Narasimham², Borja Mato³, Matic Meglic³, Chiara Perella³, Paula Pamies⁴ and Paul Emery⁵, ¹The Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Novartis Ireland Ltd, Dublin, Ireland, Dublin, Ireland, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals UK Ltd, London, UK, London, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: On an average, there is a delay of 6.7 years between symptom onset and diagnosis of axial spondyloarthritis (axSpA)1. Since traditional approaches to improving…
Abstract Number: 0047 • ACR Convergence 2021
A Role for Neutrophils in Disease Onset and Severity of Spondyloarthritis
Holly Rosenzweig¹, Emily Vance², Rouhin sen³, Liron Caplan⁴ and Ruth Napier¹, ¹Oregon Health & Science University, Portland, OR, ²VA Portland Health Care System, Portland, OR, ³Colorado University Anschutz Medical Campus, Denver, CO, ⁴Rocky Mountain Regional Veterans Affairs Medical Center (VAMC)/University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Spondyloarthritis (SpA) is a group of inflammatory diseases that includes axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). AxSpA patients have irregular neutrophil responses, as…
Abstract Number: 0359 • ACR Convergence 2021
Patient Journey with Axial Spondyloarthritis: Critical Issues from the Patient Perspective. Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Denis Poddubnyy², Christine Bundy³, Laura Christen⁴, Raj Mahapatra⁵, Souzi Makri⁶, Carlos Jesús Delgado-Domínguez⁷, Sergio Sanz-Gomez⁷, Pedro Plazuelo-Ramos⁸ and Victoria Navarro-Compán⁹, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁶Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁸Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁹Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain
Background/Purpose: The journey of axial spondyloarthritis (axSpA) for most patients is slow and arduous. The goal of this analysis is to assess the journey to…
Abstract Number: 0377 • ACR Convergence 2021
The Prevalence of Inflammatory Back Pain and HLA-B27 in a Large Population-Based Cohort in the Netherlands
Stan Kieskamp, Suzanne Arends, Elisabeth Brouwer, Hendrika Bootsma, Ilja Nolte and Anneke Spoorenberg, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Chronic low back pain (CLBP; back pain >3 months) with onset at age < 45 and inflammatory back pain (IBP) are regarded as early…
Abstract Number: 0829 • ACR Convergence 2021
Tapering and Withdrawal of Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Inflammatory Arthritis: A Systematic Review and Meta-Analyses of Randomised Trials
Line Uhrenholt¹, Robin Christensen², Wilfred K Dinesen³, Caroline Liboriussen³, Stine Andersen³, Lene Dreyer¹, Annette Schlemmer⁴, Ellen-Margrethe Hauge⁵, Conni Skrubbeltrang⁶ and Salome Kristensen¹, ¹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ²Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark, ³Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ⁴Department of Rheumatology, Randers Regional Hospital, Randers, Denmark, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Medical Library, Aalborg University Hospital, Aalborg, Denmark
Background/Purpose: Tapering and withdrawal of biological or targeted synthetic disease-modifying antirheumatic drugs (bDMARDs or tsDMARDs) in patients with inflammatory arthritis (IA) in remission or low…
Abstract Number: 0925 • ACR Convergence 2021
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs
Philip Mease¹, Robert McLean², Taylor Blachley², Maya Marchese², Laura Anatale-Tardiff³, Christopher Saffore⁴, Danny Quach⁵, Ana Biljan⁶ and Alexis Ogdie⁷, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, Waltham, MA, ⁴AbbVie, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶Abbvie Inc., Chicago, IL, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Although Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity (LDA) is a common treatment target for disease control when managing AS, real-world research…
Abstract Number: 1309 • ACR Convergence 2021
Impact of the Number of Comorbidities on the Outcome Measures and on the Retention Rate of the First Anti-TNF in Patients with Ankylosing Spondylitis: Two-year Follow-up REGISPONSER-AS
Mara ngeles Puche Larrubia¹, M.Lourdes Ladehesa-Pineda¹, Pilar Font², Alejandro Escudero Contreras³, Eduardo Collantes-Estevez² and Clementina López Medina⁴, ¹Hospital Universitario Reina Sofía, Córdoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ³Hospital Universitario Reina Sofía/IMIBIC/Universidad de Córdoba., Cordoba, Spain, ⁴Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France
Background/Purpose: a) To evaluate the impact of the number of comorbidities on the outcome measures after two years of follow-up in patients with ankylosing spondylitis…
Abstract Number: 1724 • ACR Convergence 2021
More Than 50% of Women with Chronic Rheumatic Inflammatory Diseases Present an Unfavorable Pregnancy Outcome: A Descriptive Analysis of the National French Healthcare Database
Anna Molto¹, Barbara Roux², Diep Tran², Aya Ajrouche², nathalie costedoat-Chalumeau³, Elisabeth Elefant⁴, Vassilis Tsatsaris⁵, Jeanne Fresson⁶, Brigitte Bader-Meunier⁷, Bruno Fautrel⁸ and Florence Tubach², ¹Rheumatology department, Cochin hospital, APHP, Paris, France, ²CEPHEPI, APHP, Paris, France, ³Inserm DR Paris 5, Paris, France, ⁴Teratogenic agents refernce center (CRAT) , Hôpital Trousseau, APHP, Paris, France, ⁵Obstetrics Department, Port Royal Maternity, Cochin Hospital, APHP, Paris, France, ⁶CHU Nancy, Nancy, France, ⁷Pediatric Immuno-hematology, Necker Hospital, APHP, Paris, France, ⁸Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France
Background/Purpose: Women with chronic rheumatic inflammatory diseases (CRID, i.e. rheumatoid arthritis (RA) or spondyloarthritis (SpA)) have been reported to have poorer pregnancy outcomes than the…
Abstract Number: 0048 • ACR Convergence 2021
A Novel Technology to Study the Role of Intestinal Biology in Spondyloarthritis Pathogenesis: Human Colonic Organoids and Epithelial Monolayers
Manuel Rodriguez¹, Alec Furst¹, James T. Rosenbaum² and Tejpal Gill¹, ¹Oregon Health & Science University, Portland, OR, ²Departments of Ophthalmology, Medicine, and Cell Biology, Oregon Health & Sciences University and Chair Emeritus, Legacy Devers Eye Institute, Portland, OR
Background/Purpose: Ankylosing spondylitis (AS) is a complex genetic disease with strong association to the human leukocyte antigen (HLA)-B27. Several observations including frequent, occult histologic evidence…
Abstract Number: 0360 • ACR Convergence 2021
Factors Associated with Pain Intensity in Axial Spondyloarthritis. Results from the EuropeanMap of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Christine Bundy³, Laura Christen⁴, Raj Mahapatra⁵, Souzi Makri⁶, Carlos Jesús Delgado-Domínguez⁷, José Correa-Fernández⁷, Pedro Plazuelo-Ramos⁸ and Denis Poddubnyy⁹, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁶Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁷Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁸Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain, ⁹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Pain is a hallmark of axial spondyloarthritis (axSpA) and can significantly deteriorate patients’ health status. This analysis aims to investigate factors associated with pain…
Abstract Number: 0378 • ACR Convergence 2021
Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloarthritis Patients with and Without Accompanying Familial Mediterranean Fever
Murat Kiracı¹, Emre Bilgin², Emine Duran², Bayram Farisogulları³, Ertugrul Cagri bolek⁴, Gözde Kübra Yardımcı², Zehra Ozsoy², Gizem Ayan², Gullu Sandal Uzun², Tayfun Hilmi Akbaba⁵, Banu Balci Peynircioglu⁵, Omer Karadag⁶, Ali Akdogan², Sule Apraş Bilgen², Sedat Kiraz², Ali Ihsan Ertenli², Umut Kalyoncu² and Levent Kilic², ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Hacettepe University, Ankara, Turkey, ⁴Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁵Hacettepe University, Faculty of Medicine, Department of Medical Biology, Ankara, Turkey, ⁶Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey
Background/Purpose: The co-existence rate of Familial Mediterranean Fever (FMF) and axial spondyloarthritis (axSpA) in adults is ranging from 0.5% to 7.5%. Clinical implications of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].